– USA, MA – Rhinostics Inc., an early-stage company founded by two Harvard professors to provide automated sample collection solutions for more efficient laboratory workflows, today announced the appointment of Dr. Cheri Walker, Ph.D. as President and CEO.
“Dr. Walker brings wide experience to Rhinostics, critical to driving our initiatives to make an immediate impact on COVID testing bottlenecks that plague the laboratory workflow and impact the amount of testing that can currently run through their high-throughput laboratories,” said Michael Springer, cofounder of Rhinostics and Associate Professor of Systems Biology at Harvard Medical School.
Richard Novak, Rhinostics cofounder and Senior Engineer at the Wyss Institute at Harvard University added, “She provides an energetic focus to help accomplish our mission of radically changing and improving the laboratory workflow. Her coming on board signals the next stage of growth for the company.”
About Dr. Cheri Walker
Dr. Walker brings more than two decades of experience working in life science tools and diagnostics with companies ranging from startups to those with multibillions in revenue and has closed more than 45 transactions ranging from large partnerships, licenses, mergers, acquisitions, and divestitures. She has held a variety of operating and corporate development roles at bell weather companies including Invitrogen, QIAGEN, Charles River Laboratories, and most recently as senior vice president of corporate development at Abcam. Additionally, Dr. Walker has significant startup experience, holding the position of CFO at Kailos Genetics, currently as a director at Cell IDx, and consulting with many early-stage companies. She began her career as a stock analyst at Deutsche Bank, covering life science tools companies.
Dr. Walker holds a Ph.D. in Human and Molecular Genetics from Baylor College of Medicine and a BA in Biology from Swarthmore College.
Cheri Walker added, “I am excited to join the Rhinostics team to drive the company forward, bringing new and innovative technologies to sample collection, accessioning, and transfer of samples into the workflows of high throughput laboratories. COVID testing has shined a light on the inefficiencies in this segment of the laboratory workflow, where large armies of personnel are required to manually accomplish these processes at a high cost with inefficient processes. The Rhinostics solution takes significant time, labor, and errors out of the workflow.”
About Rhinostics
Rhinostics Inc. is an early-stage company commercializing a simple and elegant solution to bring efficiencies and cost savings to the laboratory workflow. The RHINOstic nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. Additionally, the device allows the dry shipment of respiratory samples without viral transport media, and the nasal collection allows for an easy and comfortable collection. Viral samples can be released directly into a small amount of saline, providing a sample concentration of 30x or greater, providing greater standardization and improving downstream assay reliability. The product provides an immediate impact on increasing COVID testing efficiencies while applying to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction and next-generation sequencing. The RHINOstic product is registered as a Class I exempt medical device with the FDA and is available for purchase.
Rhinostics was recently formed to commercialize a nasal swab collection device with features that can increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. The product is registered as a Class I exempt medical device with the FDA, is currently being tested in several clinical trials, and the company is beginning an Emergency Use Authorization study comparing the RHINOstic swab with the gold standard for a variety of PCR assays. The product provides an immediate impact for increasing COVID testing efficiencies while applying to a broader range of respiratory viral, bacterial, and genetic testing using the polymerase chain reaction and next-generation sequencing.
For more information: https://rhinostics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
